On the third day of ATTD 2026, four cardiometabolic-related news items have been observed from Insulet, TIXiMED, Biocon, and Sana Biotechnology. Below, FENIX provides highlights and insights into the respective news items.
A series of cardiometabolic-related news items has been observed from Biocon, Novo Nordisk, Medtronic, Bloom Science, Verdiva Bio, and MHRA. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Biocon hosted its CY Q3 ’25 (FY Q2 ’26) earnings call (press release; slides) and Adocia filed a patent for its long-acting AOM platform (view press release). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lilly initiates the Ph3 MOVE-Lp(a) CVOT of muvalaplin in patients with elevated Lp(a) and ASCVD (view CT.gov record); Vivani Medical announced updated development plans for its semaglutide implant (view press release); and WHO updates essential medicines list to include Novo’s and Lilly’s GLP-1RAs (view article; view list). Below, FENIX provides highlights and insight for the respective news items.
Two cardiometabolic-related news items have been observed: Evernorth Health Services announced a new pharmacy benefit capping the monthly OOP cost of Wegovy and Zepbound (view press release); and CHMP adopted a positive opinion for the Saxenda pediatric indication (view CHMP statement). Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Lilly has stockpiled $548M worth of orforglipron in a risky move ahead of the regulatory filing/approval (view 10-K); and the CHMP agenda (view here) for this month’s meeting (Feb 24-27) has been released. Below, FEINX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: FDA issued a warning letter to a compounding facility over issues with its GLP-1RA production (view letter); Lilly has reportedly discontinued the development of volenrelaxin for HF and CKD (view article); and Teva Pharmaceuticals hosted its Q4 ’24 earnings (press release; slides). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Lilly, Insulet, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Pfizer, Merck, Fractyl Health, NewAmsterdam Pharma, and Imperial College London. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Novo Nordisk announced its CLARION-CKD Ph3 trial evaluating ocedurenone (nsMRA) failed to meet its primary endpoint (view CT.gov record; view press release); NeuroBo Pharmaceuticals announced it dosed first patients in the Part 2 MAD portion of its Ph1 trial of DA-1726 for obesity (view CT.gov record; view press release); and Hanyu Pharmaceuticals (and Hikma) announced its liraglutide ANDA has been granted tentative approval (view press release). Below, FENIX provides highlights and insights for the respective news items.